TNSN99210A1 - IDENTIFICATION OF SEN VIRUS GENOTYPES - Google Patents
IDENTIFICATION OF SEN VIRUS GENOTYPESInfo
- Publication number
- TNSN99210A1 TNSN99210A1 TNTNSN99210A TNSN99210A TNSN99210A1 TN SN99210 A1 TNSN99210 A1 TN SN99210A1 TN TNSN99210 A TNTNSN99210 A TN TNSN99210A TN SN99210 A TNSN99210 A TN SN99210A TN SN99210 A1 TNSN99210 A1 TN SN99210A1
- Authority
- TN
- Tunisia
- Prior art keywords
- acid molecule
- nucleic acid
- virus
- genome
- relates
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000003612 virological effect Effects 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- -1 PREFERABLY Substances 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000003212 astringent agent Substances 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
LA PRESENTE INVENTION SE RAPPORTE A UNE MOLECULE D'ACIDE NUCLEIQUE REPRESENTANT LE GENOME D'UN AGENT VIRAL/VIRUS, LADITE MOLECULE D'ACIDE NUCLEIQUE AYANT, AU MOINS, UNE DES CARACTERISTIQUES SUIVANTES : (a) ELLE CONTIENT, AU MOINS, UN CADRE DE LECTURE OUVERT (ORF) QUI ENCODE UN POLYPEPTIDE AYANT UNE SEQUENCE D'ACIDE AMINE DIVULGUEE DANS CE DOCUMENT, (b) ELLE COMPREND UNE SEQUENCE ADN COMME DECRIT DANS CE DOCUMENT, (c) ELLE S'HYBRIDE, DE PREFERENCE, DANS DES CONDITIONS ASTRINGENTES EN UN BRIN COMPLEMENTAIRE DE LA MOLECULE D'ACIDE NUCLEAIRE DECRITE ICI, MAIS PAS EN UN BRIN COMPLEMENTAIRE DU GENOME DU VIRUS TT ; (d) ELLE EST DEGENEREE PAR RAPPORT A LA MOLECULE D'ACIDE NUCLEIQUE HYBRIDANTE, (e) ELLE EST IDENTIQUE A, AU MOINS, 60% A LA MOLECULE D'ACIDE NUCLEIQUE REPRESENTANT LE GENOME DE L'AGENT VIRAL/VIRUS DE L'INVENTION ; ET (f) DES PARTIES DE CETTE MOLECULE PEUVENT ETRE AMPLIFIEES DANS DES CONDITIONS APPROPRIEES PAR PCR UTILISANT DES CATALYSEURS COMME DEFINI ICI. L'INVENTION SE RAPPORTE A DES VECTEURS COMPRENANT LADITE MOLECULE D'ACIDE NUCLEIQUE, DES METHODES DE PRODUCTION DE (POLY)PEPTIDE(S) ENCODES PAR LADITE MOLECULE D'ACIDE NUCLEIQUE ET ANTICORPS AUX DITS POLY(PEPTIDES)s ET/OU LESDITS AGENTS VIRUS/VIRAUX. EN PLUS, L'INVENTION SE RAPPORTE A DES COMPOSITIONS, DE PREFERENCE, DES COMPOSITIONS PHARMACEUTIQUES, DES VACCINS, DES DIAGNOSTICS ET KITS DE DIAGNOSTIC COMPRENANT OU UTILISANT DES COMPOSES DE L'INVENTION.THE PRESENT INVENTION RELATES TO A NUCLEIC ACID MOLECULE REPRESENTING THE GENOME OF A VIRAL AGENT / VIRUS, SAID NUCLEIC ACID MOLECULE HAVING AT LEAST ONE OF THE FOLLOWING CHARACTERISTICS: (a) IT CONTAINS AT LEAST ONE FRAME OPEN READER (ORF) THAT ENCODES A POLYPEPTIDE HAVING AN AMINO ACID SEQUENCE DISCLOSED IN THIS DOCUMENT, (b) IT INCLUDES A DNA SEQUENCE AS DESCRIBED IN THIS DOCUMENT, (c) IT HYBRIDIZES, PREFERABLY, UNDER CONDITIONS ASTRINGENTS IN A COMPLEMENTARY STRAND OF THE NUCLEAR ACID MOLECULE DESCRIBED HERE, BUT NOT IN A COMPLEMENTARY STRAND OF THE GENOME OF TT VIRUS; (d) IT IS DEGENERATED IN RELATION TO THE HYBRIDANT NUCLEIC ACID MOLECULE, (e) IT IS IDENTICAL TO AT LEAST 60% TO THE NUCLEIC ACID MOLECULE REPRESENTING THE VIRAL AGENT / VIRUS GENOME INVENTION; AND (f) PARTS OF THIS MOLECULE MAY BE AMPLIFIED UNDER APPROPRIATE CONDITIONS BY PCR USING CATALYSTS AS DEFINED HERE. THE INVENTION RELATES TO VECTORS COMPRISING SAID NUCLEIC ACID MOLECULE, METHODS OF PRODUCING (POLY) PEPTIDE (S) ENCODED BY SAID NUCLEIC ACID MOLECULE AND ANTIBODIES TO SAID POLY (PEPTIDES) s AND / OR SUCH AGENTS VIRUS / VIRAL. IN ADDITION, THE INVENTION RELATES TO COMPOSITIONS, PREFERABLY, PHARMACEUTICAL COMPOSITIONS, VACCINES, DIAGNOSTICS AND DIAGNOSTIC KITS COMPRISING OR USING COMPOUNDS OF THE INVENTION.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI982437 IT1303732B1 (en) | 1998-11-10 | 1998-11-10 | Nucleic acids representing the genome of the SEN virus (SENV) and encoded proteins, useful for treatment of hepatopathies, inflammatory diseases and proliferative disorders such as cancer |
| ITMI990923 IT1312552B1 (en) | 1999-04-30 | 1999-04-30 | Nucleic acids representing the genome of the SEN virus (SENV) and encoded proteins, useful for treatment of hepatopathies, inflammatory diseases and proliferative disorders such as cancer |
| EP99830298 | 1999-05-14 | ||
| EP99113932 | 1999-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN99210A1 true TNSN99210A1 (en) | 2005-11-10 |
Family
ID=27443821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN99210A TNSN99210A1 (en) | 1998-11-10 | 1999-11-08 | IDENTIFICATION OF SEN VIRUS GENOTYPES |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1137779A2 (en) |
| JP (1) | JP2002529092A (en) |
| AR (1) | AR021143A1 (en) |
| AU (1) | AU1381600A (en) |
| NO (1) | NO20012276L (en) |
| PE (1) | PE20001331A1 (en) |
| TN (1) | TNSN99210A1 (en) |
| WO (1) | WO2000028039A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2212901A (en) * | 1999-12-10 | 2001-06-18 | Roche Diagnostics Gmbh | Hepatitis virus sentinel virus i (svi) |
| DE10007234A1 (en) * | 2000-02-17 | 2001-10-18 | Sension Biolog Detektions Und | Peptide and nucleic acid coding therefor for the determination, diagnosis and therapy of diseases of the nervous system |
| DE10144346A1 (en) * | 2001-09-10 | 2003-04-03 | Deutsches Krebsforsch | TT virus sequences in human tumor tissues, means for their detection and tumor therapy |
| DK2399928T3 (en) * | 2010-06-23 | 2018-01-29 | Deutsches Krebsforsch | Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in the diagnosis, prevention and treatment of cancer and autoimmunity |
| US20110318363A1 (en) | 2010-06-23 | 2011-12-29 | Deutsches Krebsforschungszentrum | Specific TT virus sequences and chimeric TT virus host cell DNA molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity |
| DK2585477T3 (en) * | 2010-06-23 | 2018-09-03 | Deutsches Krebsforsch | RELEASED TT VIRUS MOLECULES FOR USE FOR DIAGNOSTICATION, PREVENTION AND TREATMENT OF CANCER AND AUTO-IMMUNITY |
| US9676828B2 (en) | 2010-06-23 | 2017-06-13 | Deutsches Krebsforschungszentrum | Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU741656B2 (en) * | 1997-07-25 | 2001-12-06 | Tamura, Ryoji | Non-B non-C non-G hepatitis virus gene, polynucleotide, polypeptide, virion, method for separating virion, and method for detecting virus |
| AU4259299A (en) * | 1998-05-13 | 1999-11-29 | Innogenetics N.V. | New sequences of tt viruses for use in diagnosis, prevention and treatment of ttv infections |
-
1999
- 1999-11-08 TN TNTNSN99210A patent/TNSN99210A1/en unknown
- 1999-11-09 JP JP2000581206A patent/JP2002529092A/en active Pending
- 1999-11-09 WO PCT/EP1999/008566 patent/WO2000028039A2/en not_active Ceased
- 1999-11-09 AU AU13816/00A patent/AU1381600A/en not_active Abandoned
- 1999-11-09 EP EP99971855A patent/EP1137779A2/en not_active Withdrawn
- 1999-11-10 PE PE1999001137A patent/PE20001331A1/en not_active Application Discontinuation
- 1999-11-10 AR ARP990105694A patent/AR021143A1/en not_active Application Discontinuation
-
2001
- 2001-05-09 NO NO20012276A patent/NO20012276L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1137779A2 (en) | 2001-10-04 |
| NO20012276D0 (en) | 2001-05-09 |
| PE20001331A1 (en) | 2000-12-19 |
| NO20012276L (en) | 2001-07-09 |
| JP2002529092A (en) | 2002-09-10 |
| AU1381600A (en) | 2000-05-29 |
| AR021143A1 (en) | 2002-06-12 |
| WO2000028039A2 (en) | 2000-05-18 |
| WO2000028039A3 (en) | 2000-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kos et al. | Histidine-rich stabilized polyplexes for cMet-directed tumor-targeted gene transfer | |
| EP1497467A2 (en) | Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof | |
| JP2005538696A5 (en) | ||
| EP1004670A3 (en) | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents | |
| WO2005056584A3 (en) | Novel strain of sars-associated coronavirus and applications thereof | |
| EP2298355A3 (en) | Albumin fusion proteins | |
| MA46230B1 (en) | HIV envelope protein mutations stabilizing the trimeric form | |
| TNSN99210A1 (en) | IDENTIFICATION OF SEN VIRUS GENOTYPES | |
| JPS59500498A (en) | DNA fragments derived from the L1 and L2 regions of the type 1a papillomavirus genome | |
| CA2108466A1 (en) | Hcv genomic sequences for diagnostics and therapeutics | |
| Young et al. | Different rat-derived transforming retroviruses code for an immunologically related intracellular phosphoprotein. | |
| EP1613345A4 (en) | Compositions and methods involving respiratory syncytial virus subgroup b strain 9320 | |
| WO2003022202A3 (en) | Compositions and methods for treatment of cancer | |
| WO1996021020A3 (en) | Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases | |
| WO2004014936A3 (en) | Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof | |
| EA200200743A1 (en) | RECOMBINANT REDUCTION OF THE VIRUS REPRODUCTIVE AND RESPIRATORY SYNDROME OF PIGS (PRRSV) | |
| WO2004031222A3 (en) | Dna vaccine encoding at least two nonstructural early proteins of papillomavirus | |
| EP1383796B2 (en) | Neurovirulent strain of the west nile virus and applications thereof | |
| Tognon et al. | Investigation of the simian polyomavirus SV40 as a potential causative agent of human neurological disorders in AIDS patients | |
| CA2423045A1 (en) | Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts | |
| FR2828687A1 (en) | NOVEL PEPTIDES AND THEIR USE AS MEDICAMENTS AGAINST IVF INFECTION IN CATS | |
| US20240218347A1 (en) | Polymer of Protein-Conjugated Polysaccharide, Preparation Method Therefor, Enzyme-Stabilizing Composition Comprising Same, and Method for Detecting Target Nucleic Acid Molecule by Using Same | |
| EP0743364A3 (en) | Nucleic acid fragments derived form the HIV-1 genome, corresponding fragments and their application as reactives for risk evaluation of HIV-1 mother-foetal transmission | |
| US20250270525A1 (en) | Methods and compositions relating to a group ii intron reverse transcriptase | |
| WO2003051174A3 (en) | Single nucleotide polymorphisms and mutations on alpha-2-macroglobulin |